News on Medial

PlaySuper raises $500K in seed round led by IAN Group and 100X.VC

EntrackrEntrackr · 5m ago
PlaySuper raises $500K in seed round led by IAN Group and 100X.VC
Medial

Snippets PlaySuper raises $500K in seed round led by IAN Group and 100X.VC Gaming commerce startup PlaySuper has raised $500K in its seed round led by IAN Angel Fund and 100X.VC. The round also saw participation from angel investors including Uday Sodhi, KRS Jamwal, Pratham Mittal, Rajit Bhattacharya, and Ankit Das, among others. The proceeds will be used to accelerate product development, expand market reach, and strengthen hiring. PlaySuper is set to launch its next-gen, hyper-personalized in-game store, allowing easy integration without requiring updates. The Gurugram-based brand also plans to expand into Southeast Asia (SEA) within six months, followed by MENA and LATAM. Additionally, it will bring in a Product Head and expand its B2B partnerships team to onboard more gaming studios. Founded in April 2024 by Shouradeep Chakraborty, PlaySuper enables gamers to shop inside their favorite mobile games while playing. It integrates real-world shopping experiences within mobile games. Shouradeep and Upamanyu previously co-founded LectureNotes, an edtech platform that raised $2.5 million in 2022. They bring extensive experience from the gaming, Web3, and edtech sectors. Over the next year, the company will focus on launching its in-game store, scaling its reach into new markets, and deepening its collaborations with game developers.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr · 10d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IAN’s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions—ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.